Loading
Olvimulogene nanivacirepvec is an experimental oncolytic virus from Genelux in phase 3 trials for ovarian cancer and non-small-cell lung cancer, with its target not yet stated publicly.
Olvimulogene nanivacirepvec is an oncolytic virus developed by Genelux. Its molecular target is not stated in the ClinicalTrials.gov intervention record, and OnCo has not confirmed one from the sponsor's pipeline page. ClinicalTrials.gov describes the intervention as: Olvi-Vec is an engineered oncolytic vaccinia virus. It is the investigational product in 2 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including the phase 3 study NCT05281471 (Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)), in ovarian cancer and non-small-cell lung cancer. The largest, NCT05281471, plans to enrol 186 participants with primary completion expected 2026-12. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
Mechanism not stated in the ClinicalTrials.gov record or on the sponsor's pipeline page.
1.Olvimulogene nanivacirepvec slips into a pocket on its target.
Background: ADC sequencing, Antigen escape (antigen loss, lineage switch), BCG-unresponsive, Castration-resistant prostate cancer (CRPC), Circulating tumour DNA (ctDNA). Also on OnCo: Resistance: how tumours escape each drug class · Lines of therapy.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Olvimulogene nanivacirepvec" OR ABSTRACT:"Olvimulogene nanivacirepvec" OR TITLE:"GL-ONC1 and GLV-1h68" OR ABSTRACT:"GL-ONC1 and GLV-1h68" OR TITLE:"Olvi-Vec" OR ABSTRACT:"Olvi-Vec" OR TITLE:"GL-ONC" OR ABSTRACT:"GL-ONC" OR TITLE:"GLV-1h68" OR ABSTRACT:"GLV-1h68") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Olvimulogene nanivacirepvec, not a curated reading list.
Shares Ovarian cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Ovarian cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Ovarian cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Ovarian cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Ovarian cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Ovarian cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Ovarian cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Ovarian cancer, Non-small-cell lung cancer and the tag pipeline.